(IPN) Ipsen - Ratings and Ratios
Exchange: PA • Country: France • Currency: EUR • Type: Common Stock • ISIN: FR0010259150
IPN: Cabometyx, Somatuline, Decapeptyl, Dysport, Onivyde
Ipsen S.A. (PA:IPN) is a global biopharmaceutical company specializing in oncology, neuroscience, and rare diseases. Its pipeline includes Cabometyx + Atezolizumab (Phase III for second-line metastatic castration-resistant prostate cancer), lenalidomide and rituximab (Phase III for second-line follicular lymphoma), Bylvay (Phase III for biliary atresia), Dysport (Phase III for chronic and episodic migraine), Fidrisertib (Phase II for fibrodysplasia ossificans progressiva), Elafibranor (Phase II for primary sclerosing cholangitis), and IPN60250. Additional compounds in development include IPN10200 (Phase II for longer-acting neurotoxin aesthetics and therapeutics), IPN60210 (Phase I for relapsed/refractory multiple myeloma), and IPN60260 (Phase I for viral cholestatic disease). The company markets products such as Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, Dysport, Bylvay, NutropinAq, Increlex, and Sohonos. Founded in 1929, Ipsen is headquartered in Boulogne-Billancourt, France. Web URL: https://www.ipsen.com.
As of the latest data, Ipsen S.A. (PA:IPN) has a market capitalization of 7819.79M EUR, with a price-to-earnings ratio of 22.14 and a forward P/E of 9.35. The price-to-book ratio is 1.87, and the price-to-sales ratio is 2.19. Return on equity stands at 23.68. The stock is trading at 98.35, below its 20-day (99.83), 50-day (106.62), and 200-day (110.18) moving averages, with an average true range (ATR) of 3.08.
Additional Sources for IPN Stock
IPN Stock Overview
| Market Cap in USD | 9,298m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2005-12-07 |
IPN Stock Ratings
| Growth Rating | 40.4 |
| Fundamental | 79.9 |
| Dividend Rating | 58.2 |
| Rel. Strength | -11.1 |
| Analysts | - |
| Fair Price Momentum | 96.10 EUR |
| Fair Price DCF | 418.14 EUR |
IPN Dividends
| Dividend Yield 12m | 2.44% |
| Yield on Cost 5y | 4.21% |
| Annual Growth 5y | 3.71% |
| Payout Consistency | 97.2% |
IPN Growth Ratios
| Growth Correlation 3m | -90.3% |
| Growth Correlation 12m | -30.5% |
| Growth Correlation 5y | 86.5% |
| CAGR 5y | 10.35% |
| CAGR/Max DD 5y | 0.33 |
| Sharpe Ratio 12m | -0.16 |
| Alpha | -16.65 |
| Beta | 0.098 |
| Volatility | 31.62% |
| Current Volume | 130.9k |
| Average Volume 20d | 98.1k |
As of May 01, 2025, the stock is trading at EUR 102.10 with a total of 130,863 shares traded.
Over the past week, the price has changed by +7.81%, over one month by -4.04%, over three months by -14.35% and over the past year by -9.61%.
Yes, based on ValueRay Fundamental Analyses, Ipsen (PA:IPN) is currently (May 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 79.90 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IPN as of May 2025 is 96.10. This means that IPN is currently overvalued and has a potential downside of -5.88%.
Ipsen has no consensus analysts rating.
According to ValueRays Forecast Model, IPN Ipsen will be worth about 103.8 in May 2026. The stock is currently trading at 102.10. This means that the stock has a potential upside of +1.66%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 125.5 | 22.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 103.8 | 1.7% |